Trade Aligos Therapeutics, Inc. - ALGS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0098 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Aligos Therapeutics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.6886 |
Open* | 0.7076 |
1-Year Change* | -27.71% |
Day's Range* | 0.6938 - 0.7277 |
52 wk Range | 0.54-2.41 |
Average Volume (10 days) | 77.27K |
Average Volume (3 months) | 1.65M |
Market Cap | 48.86M |
P/E Ratio | -100.00K |
Shares Outstanding | 74.93M |
Revenue | 16.39M |
EPS | -1.90 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 0.6938 | -0.0138 | -1.95% | 0.7076 | 0.7277 | 0.6938 |
Nov 30, 2023 | 0.6886 | -0.0345 | -4.77% | 0.7231 | 0.7231 | 0.6776 |
Nov 29, 2023 | 0.6876 | 0.0100 | 1.48% | 0.6776 | 0.7116 | 0.6776 |
Nov 28, 2023 | 0.6924 | -0.0052 | -0.75% | 0.6976 | 0.7276 | 0.6680 |
Nov 27, 2023 | 0.7276 | 0.0090 | 1.25% | 0.7186 | 0.7353 | 0.7136 |
Nov 24, 2023 | 0.7121 | 0.0645 | 9.96% | 0.6476 | 0.7321 | 0.6476 |
Nov 22, 2023 | 0.6674 | -0.0258 | -3.72% | 0.6932 | 0.7230 | 0.6674 |
Nov 21, 2023 | 0.6486 | -0.0290 | -4.28% | 0.6776 | 0.6776 | 0.6485 |
Nov 20, 2023 | 0.6876 | 0.0300 | 4.56% | 0.6576 | 0.7076 | 0.6476 |
Nov 17, 2023 | 0.6576 | -0.0401 | -5.75% | 0.6977 | 0.6977 | 0.6476 |
Nov 16, 2023 | 0.6196 | 0.0109 | 1.79% | 0.6087 | 0.6535 | 0.6087 |
Nov 15, 2023 | 0.6076 | -0.0298 | -4.68% | 0.6374 | 0.6670 | 0.6076 |
Nov 14, 2023 | 0.5886 | -0.0078 | -1.31% | 0.5964 | 0.6186 | 0.5726 |
Nov 13, 2023 | 0.5776 | -0.1500 | -20.62% | 0.7276 | 0.7276 | 0.5526 |
Nov 10, 2023 | 0.6769 | -0.0657 | -8.85% | 0.7426 | 0.7462 | 0.6401 |
Nov 9, 2023 | 0.7576 | 0.0100 | 1.34% | 0.7476 | 0.7576 | 0.7314 |
Nov 8, 2023 | 0.7089 | -0.0219 | -3.00% | 0.7308 | 0.7450 | 0.6868 |
Nov 7, 2023 | 0.7326 | -0.0050 | -0.68% | 0.7376 | 0.7465 | 0.7152 |
Nov 6, 2023 | 0.7568 | -0.0408 | -5.12% | 0.7976 | 0.8128 | 0.7449 |
Nov 3, 2023 | 0.7578 | 0.0202 | 2.74% | 0.7376 | 0.7579 | 0.7276 |
Aligos Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 7, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Aligos Therapeutics Inc Earnings Release Q4 2023 Aligos Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 13.907 | 4.359 | 0 | 0 | 0 |
Total Operating Expense | 111.487 | 132.68 | 97.834 | 54.043 | 14.094 |
Selling/General/Admin. Expenses, Total | 26.41 | 28.527 | 17.944 | 10.005 | 3.205 |
Research & Development | 85.077 | 104.153 | 79.89 | 43.354 | 10.39 |
Depreciation / Amortization | 0.684 | 0.066 | |||
Unusual Expense (Income) | 0.433 | ||||
Operating Income | -97.58 | -128.321 | -97.834 | -54.043 | -14.094 |
Interest Income (Expense), Net Non-Operating | 1.521 | 0.242 | 1.256 | 1.562 | 0.163 |
Other, Net | 0.119 | -0.11 | -11.804 | 0.302 | -0.002 |
Net Income Before Taxes | -95.94 | -128.189 | -108.382 | -52.179 | -13.933 |
Net Income After Taxes | -96.046 | -128.332 | -108.543 | -52.264 | -13.933 |
Net Income Before Extra. Items | -96.046 | -128.332 | -108.543 | -52.264 | -13.933 |
Net Income | -96.046 | -128.332 | -108.543 | -52.264 | -13.933 |
Income Available to Common Excl. Extra. Items | -96.046 | -128.332 | -108.543 | -52.264 | -13.933 |
Income Available to Common Incl. Extra. Items | -96.046 | -128.332 | -108.543 | -52.264 | -13.933 |
Diluted Net Income | -96.046 | -128.332 | -108.543 | -52.264 | -13.933 |
Diluted Weighted Average Shares | 42.6952 | 39.8554 | 36.6063 | 36.8902 | 36.8902 |
Diluted EPS Excluding Extraordinary Items | -2.24957 | -3.21994 | -2.96515 | -1.41675 | -0.37769 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -2.24957 | -3.21994 | -2.96515 | -1.41675 | -0.36595 |
Revenue | 13.907 | 4.359 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 6.886 | 2.723 | 3.537 | 4.106 | 3.693 |
Revenue | 6.886 | 2.723 | 3.537 | 4.106 | 3.693 |
Total Operating Expense | 26.027 | 26.641 | 26.219 | 23.054 | 24.086 |
Selling/General/Admin. Expenses, Total | 6.246 | 5.006 | 7.119 | 5.263 | 7.576 |
Research & Development | 16.781 | 18.135 | 19.1 | 17.791 | 16.51 |
Operating Income | -19.141 | -23.918 | -22.682 | -18.948 | -20.393 |
Interest Income (Expense), Net Non-Operating | 0.955 | 0.748 | 0.757 | 0.466 | 0.212 |
Other, Net | 0.152 | 0.254 | 0.088 | -0.182 | 0.304 |
Net Income Before Taxes | -18.034 | -22.916 | -21.837 | -18.664 | -19.877 |
Net Income After Taxes | -18.791 | -22.955 | -21.886 | -18.621 | -19.924 |
Net Income Before Extra. Items | -18.791 | -22.955 | -21.886 | -18.621 | -19.924 |
Net Income | -18.791 | -22.955 | -21.886 | -18.621 | -19.924 |
Income Available to Common Excl. Extra. Items | -18.791 | -22.955 | -21.886 | -18.621 | -19.924 |
Income Available to Common Incl. Extra. Items | -18.791 | -22.955 | -21.886 | -18.621 | -19.924 |
Diluted Net Income | -18.791 | -22.955 | -21.886 | -18.621 | -19.924 |
Diluted Weighted Average Shares | 43.2155 | 42.9101 | 42.8377 | 42.7619 | 42.6656 |
Diluted EPS Excluding Extraordinary Items | -0.43482 | -0.53496 | -0.5109 | -0.43546 | -0.46698 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.3897 | -0.48194 | -0.5109 | -0.43546 | -0.46698 |
Unusual Expense (Income) | 3 | 3.5 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 133.545 | 204.424 | 250.017 | 120.226 | 92.369 |
Cash and Short Term Investments | 125.827 | 190.734 | 243.513 | 117.663 | 90.852 |
Cash & Equivalents | 81.347 | 186.816 | 220.383 | 69.565 | 24.035 |
Short Term Investments | 44.48 | 3.918 | 23.13 | 48.098 | 66.817 |
Other Current Assets, Total | 7.718 | 13.69 | 6.504 | 2.563 | 1.517 |
Total Assets | 146.693 | 235.369 | 265.302 | 146.52 | 107.731 |
Property/Plant/Equipment, Total - Net | 12.514 | 14.969 | 14.908 | 16.087 | 15.184 |
Property/Plant/Equipment, Total - Gross | 22.082 | 22.231 | 19.151 | 17.595 | 15.296 |
Accumulated Depreciation, Total | -9.568 | -7.262 | -4.243 | -1.508 | -0.112 |
Long Term Investments | 0 | 15.11 | 10.019 | 0 | |
Other Long Term Assets, Total | 0.634 | 0.866 | 0.377 | 0.188 | 0.178 |
Total Current Liabilities | 33.129 | 38.957 | 30.274 | 13.818 | 7.489 |
Accounts Payable | 4.737 | 3.015 | 3.313 | 3.767 | 2.977 |
Accrued Expenses | 17.535 | 26.652 | 18.27 | 8.702 | 4.389 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.108 | 0.138 | 0.064 | 0.074 | 0.01 |
Other Current Liabilities, Total | 10.749 | 9.152 | 8.627 | 1.275 | 0.113 |
Total Liabilities | 42.793 | 50.638 | 45.263 | 29.332 | 20.96 |
Total Long Term Debt | 0.23 | 0.394 | 0.509 | 3.352 | 0.026 |
Long Term Debt | 0 | 0.133 | 0.379 | 3.174 | 0 |
Capital Lease Obligations | 0.23 | 0.261 | 0.13 | 0.178 | 0.026 |
Other Liabilities, Total | 9.434 | 11.287 | 14.48 | 12.162 | 13.445 |
Total Equity | 103.9 | 184.731 | 220.039 | 117.188 | 86.771 |
Redeemable Preferred Stock | 0 | 0 | 182.079 | 100.519 | |
Common Stock | 0.004 | 0.004 | 0.004 | 0.004 | 0.003 |
Additional Paid-In Capital | 502.613 | 487.347 | 394.963 | 1.417 | 0.179 |
Retained Earnings (Accumulated Deficit) | -399.118 | -303.072 | -174.74 | -66.197 | -13.933 |
Other Equity, Total | 0.401 | 0.452 | -0.188 | -0.115 | 0.003 |
Total Liabilities & Shareholders’ Equity | 146.693 | 235.369 | 265.302 | 146.52 | 107.731 |
Total Common Shares Outstanding | 42.9401 | 42.6941 | 39.6986 | 36.8902 | 36.8902 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 74.643 | 94.243 | 109.429 | 133.545 | 150.093 |
Cash and Short Term Investments | 70.429 | 90.838 | 103.516 | 125.827 | 142.304 |
Cash & Equivalents | 70.429 | 90.828 | 78.671 | 81.347 | 86.44 |
Short Term Investments | 0 | 0.01 | 24.845 | 44.48 | 55.864 |
Other Current Assets, Total | 4.214 | 3.405 | 5.913 | 7.718 | 7.789 |
Total Assets | 85.852 | 106.13 | 121.738 | 146.693 | 164.069 |
Property/Plant/Equipment, Total - Net | 10.586 | 11.263 | 11.677 | 12.514 | 13.323 |
Property/Plant/Equipment, Total - Gross | 21.318 | 21.689 | 21.699 | 22.082 | 22.369 |
Accumulated Depreciation, Total | -10.732 | -10.426 | -10.022 | -9.568 | -9.046 |
Other Long Term Assets, Total | 0.623 | 0.624 | 0.632 | 0.634 | 0.653 |
Total Current Liabilities | 22.468 | 27.225 | 28.079 | 33.129 | 30.541 |
Accounts Payable | 2.941 | 3.241 | 2.822 | 4.737 | 2.931 |
Accrued Expenses | 14.253 | 15.502 | 15.807 | 17.535 | 15.748 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.058 | 0.064 | 0.108 | 0.108 | 0.138 |
Other Current Liabilities, Total | 5.216 | 8.418 | 9.342 | 10.749 | 11.724 |
Total Liabilities | 31.031 | 36.495 | 36.988 | 42.793 | 42.056 |
Total Long Term Debt | 0.188 | 0.203 | 0.205 | 0.23 | 0.174 |
Capital Lease Obligations | 0.188 | 0.203 | 0.205 | 0.23 | 0.174 |
Other Liabilities, Total | 8.375 | 9.067 | 8.704 | 9.434 | 11.341 |
Total Equity | 54.821 | 69.635 | 84.75 | 103.9 | 122.013 |
Redeemable Preferred Stock | 0 | ||||
Common Stock | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
Additional Paid-In Capital | 513.225 | 509.998 | 506.32 | 502.613 | 499.082 |
Retained Earnings (Accumulated Deficit) | -458.905 | -440.864 | -422.073 | -399.118 | -377.232 |
Other Equity, Total | 0.497 | 0.497 | 0.499 | 0.401 | 0.159 |
Total Liabilities & Shareholders’ Equity | 85.852 | 106.13 | 121.738 | 146.693 | 164.069 |
Total Common Shares Outstanding | 43.5026 | 43.5026 | 42.9401 | 42.9401 | 45.9079 |
Long Term Debt | 0 | ||||
Long Term Investments | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -96.046 | -128.332 | -108.543 | -52.264 | -13.933 |
Cash From Operating Activities | -79.389 | -115.662 | -74.263 | -46.767 | -6.049 |
Cash From Operating Activities | 2.306 | 3.019 | 2.735 | 2.299 | 1.291 |
Non-Cash Items | 15.903 | 14.302 | 15.482 | -0.473 | 1.708 |
Cash Taxes Paid | 0 | 0 | 0.001 | 0 | |
Cash Interest Paid | 0 | 0 | 0 | 0.006 | 0 |
Changes in Working Capital | -1.552 | -4.651 | 16.063 | 3.671 | 4.885 |
Cash From Investing Activities | -26.293 | 3.022 | 32.755 | 6.791 | -69.289 |
Capital Expenditures | -0.943 | -0.892 | -2.064 | -2.786 | -2.516 |
Other Investing Cash Flow Items, Total | -25.35 | 3.914 | 34.819 | 9.577 | -66.773 |
Cash From Financing Activities | 0.164 | 78.677 | 192.348 | 85.532 | 99.885 |
Issuance (Retirement) of Stock, Net | 0.225 | 79.631 | 196.522 | 85.575 | 94.885 |
Issuance (Retirement) of Debt, Net | -0.061 | -0.079 | -0.058 | -0.043 | 5 |
Net Change in Cash | -105.518 | -33.963 | 150.84 | 45.556 | 24.547 |
Financing Cash Flow Items | -0.875 | -4.116 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -22.955 | -96.046 | -74.16 | -55.539 | -35.615 |
Cash From Operating Activities | -22.387 | -79.389 | -62.606 | -45.469 | -20.434 |
Cash From Operating Activities | 0.454 | 2.306 | 1.784 | 1.246 | 0.676 |
Non-Cash Items | 3.787 | 15.903 | 12.187 | 8.397 | 4.102 |
Cash Interest Paid | 0 | 0 | 0 | ||
Changes in Working Capital | -3.673 | -1.552 | -2.417 | 0.427 | 10.403 |
Cash From Investing Activities | 19.993 | -26.293 | -37.897 | -70.38 | -60.404 |
Capital Expenditures | -0.007 | -0.943 | -0.852 | -0.849 | -0.515 |
Other Investing Cash Flow Items, Total | 20 | -25.35 | -37.045 | -69.531 | -59.889 |
Cash From Financing Activities | -0.001 | 0.164 | 0.043 | 0.062 | -0.021 |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Stock, Net | 0.023 | 0.225 | 0.131 | 0.122 | 0.01 |
Issuance (Retirement) of Debt, Net | -0.024 | -0.061 | -0.088 | -0.06 | -0.031 |
Net Change in Cash | -2.395 | -105.518 | -100.46 | -115.787 | -80.859 |
Cash Taxes Paid | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
EcoR1 Capital, LLC | Hedge Fund | 5.4961 | 3948360 | 0 | 2023-06-30 | LOW |
Vivo Capital, LLC | Venture Capital | 4.9374 | 3547030 | 0 | 2023-06-30 | LOW |
Tang Capital Management, LLC | Hedge Fund | 4.634 | 3329048 | -95752 | 2023-06-30 | MED |
Roche Holding AG | Holding Company | 4.3045 | 3092340 | 0 | 2023-04-27 | |
Versant Ventures | Venture Capital | 3.23 | 2320381 | 0 | 2023-06-30 | LOW |
HHLR Advisors, Ltd. | Investment Advisor/Hedge Fund | 3.2152 | 2309764 | 0 | 2023-06-30 | MED |
Blatt (Lawrence M) | Individual Investor | 2.9519 | 2120633 | 610277 | 2023-10-25 | |
Baker Bros. Advisors LP | Hedge Fund | 2.8903 | 2076400 | 0 | 2023-06-30 | LOW |
Beigelman (Leonid) | Individual Investor | 2.1024 | 1510352 | 0 | 2023-04-27 | |
Adage Capital Management, L.P. | Hedge Fund | 1.7028 | 1223278 | 0 | 2023-06-30 | LOW |
BofA Global Research (US) | Research Firm | 1.6021 | 1150945 | 3162 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.3846 | 994712 | -21969 | 2023-06-30 | LOW |
Newtyn Management, LLC | Hedge Fund | 1.2528 | 900000 | -121461 | 2023-06-30 | MED |
RBC Capital Markets Wealth Management | Research Firm | 1.1693 | 840030 | 795328 | 2023-06-30 | LOW |
Pivotal Bioventure Partners Investment Advisor LLC | Venture Capital | 1.0345 | 743215 | 0 | 2023-06-30 | LOW |
SilverArc Capital Management, LLC | Hedge Fund | 0.8796 | 631887 | 0 | 2023-06-30 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.7861 | 564715 | 0 | 2023-06-30 | MED |
Renaissance Technologies LLC | Hedge Fund | 0.5993 | 430555 | -22305 | 2023-06-30 | HIGH |
Symons (Julian A) | Individual Investor | 0.5485 | 394064 | 0 | 2023-04-27 | |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.3866 | 277728 | -7138 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Aligos Therapeutics, Inc. Company profile
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aligos Therapeutics Inc revenues increased from $0K to $4.4M. Net loss increased 18% to $128.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 12% to $88.3M (expense), Stock-based Compensation in R&D increase from $1M to $7.6M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
One Corporate Dr., 2Nd Floor
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com